Home > Newsletters > Drug Industry Daily > Eli Lilly Ad for Alzheimer’s PET Drug Draws Untitled Letter for Misleading Imagery
Drug Industry Daily
Sept. 10, 2012 | Vol. 11 No. 177
Eli Lilly Ad for Alzheimer’s PET Drug Draws Untitled Letter for Misleading Imagery
Eli Lilly has misbranded its radioactive PET drug Amyvid, approved for reviewing displays of brain scans using a black-and-white scale, by featuring a multi-colored brain image on a webpage advertisement and other promotional materials for the product, according to an FDA untitled letter.
ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnewsAll rights reserved. Do not duplicate or redistribute in any form.